Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2024.

HRMY : 34.28 (+1.15%)
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript

HRMY earnings call for the period ending June 30, 2024.

HRMY : 34.28 (+1.15%)
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript

HRMY earnings call for the period ending March 31, 2024.

HRMY : 34.28 (+1.15%)
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript

HRMY earnings call for the period ending December 31, 2023.

HRMY : 34.28 (+1.15%)
Why Harmony Biosciences Stock Got Slammed Today

The commercial-stage company was dinged by a bearish new take from a researcher.

BAC : 44.17 (+1.82%)
HRMY : 34.28 (+1.15%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.0600 (+6.00%)
CARA : 0.4226 (+3.35%)
CRBP : 13.00 (-2.48%)
HRMY : 34.28 (+1.15%)
JAZZ : 122.97 (+0.10%)
Harmony Biosciences (HRMY) Q3 2023 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2023.

HRMY : 34.28 (+1.15%)
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...

HRMY : 34.28 (+1.15%)
Wells Fargo, JPMorgan Chase rise; Harmony Biosciences, Belden fall, Friday, 10/13/2023

Stocks that traded heavily or had substantial price changes on Friday: Wells Fargo, JPMorgan Chase rise; Harmony Biosciences, Belden fall

WFC : 70.34 (+2.16%)
HRMY : 34.28 (+1.15%)
C : 69.19 (+1.13%)
CMTL : 3.69 (+22.59%)
DG : 76.40 (+3.40%)
UNH : 500.13 (+2.22%)
JPM : 237.60 (+1.99%)
Why Shares of Harmony Bioscience Are Falling on Friday

The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.

ZYNE : 1.3000 (+2.36%)
HRMY : 34.28 (+1.15%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar